Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIFC NASDAQ:KLRS NASDAQ:ONCY NASDAQ:SKYE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIFCALT5 Sigma$0.67+5.9%$0.85$0.61▼$10.38$88.43M1.711.36 million shs2.02 million shsKLRSKalaris Therapeutics$4.72+3.7%$5.23$2.14▼$11.88$108.25M0.1572,680 shs235,548 shsONCYOncolytics Biotech$0.96+3.0%$0.92$0.56▼$1.51$111.21M1.071.70 million shs1.13 million shsSKYESkye Bioscience$0.71-0.6%$0.81$0.57▼$5.75$25M2.95187,999 shs156,436 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIFCALT5 Sigma-8.88%-3.14%-30.38%-55.78%-92.33%KLRSKalaris Therapeutics+4.12%+9.37%-4.01%-33.19%+77.73%ONCYOncolytics Biotech-1.86%+16.46%+16.46%-4.81%+39.47%SKYESkye Bioscience-0.96%-8.78%-8.51%+7.80%-65.71%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIFCALT5 Sigma$0.67+5.9%$0.85$0.61▼$10.38$88.43M1.711.36 million shs2.02 million shsKLRSKalaris Therapeutics$4.72+3.7%$5.23$2.14▼$11.88$108.25M0.1572,680 shs235,548 shsONCYOncolytics Biotech$0.96+3.0%$0.92$0.56▼$1.51$111.21M1.071.70 million shs1.13 million shsSKYESkye Bioscience$0.71-0.6%$0.81$0.57▼$5.75$25M2.95187,999 shs156,436 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIFCALT5 Sigma-8.88%-3.14%-30.38%-55.78%-92.33%KLRSKalaris Therapeutics+4.12%+9.37%-4.01%-33.19%+77.73%ONCYOncolytics Biotech-1.86%+16.46%+16.46%-4.81%+39.47%SKYESkye Bioscience-0.96%-8.78%-8.51%+7.80%-65.71%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIFCALT5 Sigma 1.00SellN/AN/AKLRSKalaris Therapeutics 2.78Moderate Buy$15.60230.51% UpsideONCYOncolytics Biotech 2.75Moderate Buy$8.50785.42% UpsideSKYESkye Bioscience 2.57Moderate Buy$9.801,285.55% UpsideCurrent Analyst Ratings BreakdownLatest SKYE, AIFC, KLRS, and ONCY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/15/2026KLRSKalaris Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy6/11/2026ONCYOncolytics Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/9/2026KLRSKalaris Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/29/2026ONCYOncolytics Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/26/2026ONCYOncolytics Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.005/14/2026KLRSKalaris Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$17.005/14/2026KLRSKalaris Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$17.005/13/2026KLRSKalaris Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/13/2026KLRSKalaris Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$26.00 ➝ $25.005/8/2026ONCYOncolytics Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/24/2026ONCYOncolytics Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)(Data available from 6/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIFCALT5 Sigma$24.84M3.77N/AN/A$9.07 per share0.07KLRSKalaris TherapeuticsN/AN/AN/AN/A$4.21 per shareN/AONCYOncolytics BiotechN/AN/AN/AN/A($0.04) per shareN/ASKYESkye BioscienceN/AN/AN/AN/A$0.62 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIFCALT5 Sigma-$344.51MN/AN/AN/AN/A-2,483.94%-68.25%-62.43%N/AKLRSKalaris Therapeutics-$43.44M-$2.15N/AN/AN/AN/A-72.78%-43.49%N/AONCYOncolytics Biotech-$28.76M-$0.31N/AN/AN/AN/A-2,185.97%-321.54%7/31/2026 (Estimated)SKYESkye Bioscience-$55.92M-$1.44N/AN/AN/AN/A-217.27%-162.39%N/ALatest SKYE, AIFC, KLRS, and ONCY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/18/2026Q1 2026AIFCALT5 SigmaN/A-$2.14N/A-$2.14N/A$4.71 million5/14/2026Q1 2026ONCYOncolytics Biotech-$0.05-$0.08-$0.03-$0.08N/AN/A5/12/2026Q1 2026KLRSKalaris Therapeutics-$0.52-$0.46+$0.06-$0.46N/AN/A5/11/2026Q1 2026SKYESkye Bioscience-$0.29-$0.32-$0.03-$0.32N/AN/A4/11/2026Q4 2025AIFCALT5 SigmaN/A-$6.19N/A-$6.19N/A$5.37 million3/31/2026Q4 2025ONCYOncolytics Biotech-$0.06-$0.08-$0.02-$0.08N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAIFCALT5 SigmaN/AN/AN/AN/AN/AKLRSKalaris TherapeuticsN/AN/AN/AN/AN/AONCYOncolytics BiotechN/AN/AN/AN/AN/ASKYESkye BioscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIFCALT5 Sigma0.030.820.82KLRSKalaris TherapeuticsN/A12.1912.19ONCYOncolytics BiotechN/A1.381.38SKYESkye BioscienceN/A1.781.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIFCALT5 Sigma6.27%KLRSKalaris Therapeutics66.05%ONCYOncolytics Biotech6.82%SKYESkye Bioscience21.09%Insider OwnershipCompanyInsider OwnershipAIFCALT5 Sigma0.21%KLRSKalaris Therapeutics68.10%ONCYOncolytics Biotech0.10%SKYESkye Bioscience6.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIFCALT5 Sigma170139.84 million139.54 millionN/AKLRSKalaris Therapeutics11023.79 million7.59 millionN/AONCYOncolytics Biotech30119.35 million119.24 millionNot OptionableSKYESkye Bioscience1135.14 million32.97 millionOptionableSKYE, AIFC, KLRS, and ONCY HeadlinesRecent News About These CompaniesSkye Bioscience, Inc. (NASDAQ:SKYE) Receives Average Rating of "Moderate Buy" from BrokeragesJune 18 at 2:44 AM | americanbankingnews.comSkye Bioscience (NASDAQ:SKYE) Stock Price Down 7.3% - Should You Sell?June 16 at 1:42 AM | americanbankingnews.comSkye Bioscience Expands Authorized Shares After Shareholder ApprovalMay 29, 2026 | tipranks.comSkye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1May 20, 2026 | globenewswire.comSkye Bioscience (SKYE) price target decreased by 11.48% to 7.87May 14, 2026 | msn.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Coherus Biosciences (CHRS), Moderna (MRNA) and Skye Bioscience (SKYE)May 14, 2026 | theglobeandmail.comSkye Bioscience, Inc.: Skye Bioscience Reports First Quarter 2026 Financial Results and Business UpdateMay 14, 2026 | finanznachrichten.dePomerantz LLP Files Investor Lawsuit Against Skye Bioscience, Inc. – SKYEMay 13, 2026 | natlawreview.comNSkye Bioscience Initiates CBeyond™ Expansion Study (Part C) with Planned Review on May 18, 2026May 12, 2026 | quiverquant.comQUPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business UpdateMay 12, 2026 | globenewswire.comSkye Bioscience Reports First Quarter 2026 Financial Results and Business UpdateMay 11, 2026 | globenewswire.comKuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law FirmApril 22, 2026 | globenewswire.comSkye Bioscience Presenting at GLP-1-Based Therapeutics SummitApril 7, 2026 | globenewswire.comSkye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination DevelopmentApril 2, 2026 | globenewswire.comSkye Bioscience Inc (SKYE) Q4 2025 Earnings Call Highlights: Pioneering Advances in Obesity ...March 11, 2026 | finance.yahoo.comSkye Bioscience, Inc.: Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateMarch 11, 2026 | finanznachrichten.deSkye Bioscience outlines 2026 milestones as nimacimab advances toward Phase IIb with new dosing strategyMarch 11, 2026 | msn.comSkye Bioscience, Inc. (SKYE) Q4 2025 Earnings Call TranscriptMarch 10, 2026 | seekingalpha.comSkye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateMarch 10, 2026 | globenewswire.comSkye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026March 5, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSKYE, AIFC, KLRS, and ONCY Company DescriptionsALT5 Sigma NASDAQ:AIFC$0.67 +0.04 (+5.87%) As of 04:00 PM EasternALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.Kalaris Therapeutics NASDAQ:KLRS$4.72 +0.17 (+3.74%) Closing price 04:00 PM EasternExtended Trading$4.56 -0.16 (-3.39%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.Oncolytics Biotech NASDAQ:ONCY$0.96 +0.03 (+3.03%) Closing price 04:00 PM EasternExtended Trading$0.95 -0.01 (-0.63%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.Skye Bioscience NASDAQ:SKYE$0.71 0.00 (-0.59%) Closing price 04:00 PM EasternExtended Trading$0.73 +0.03 (+3.77%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge Jabil Just Gave Investors a Stronger Reason to Buy the Dip USA Rare Earth Just Moved Closer to Commercial Reality After an Initial Panic, Wall Street's Leaning Into Apple's New Siri AI CoreWeave Insider Sales Look Big, But Should Investors Worry? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
